[Porphyria].
Hasui
Yasuhiro
Y
Department of Neuropsychiatry, Ehime University School of Medicine.
Ikeda
Manabu
M
Tanabe
Hirotaka
H
D000624:5-Aminolevulinate Synthetase; D000701:Analgesics, Opioid / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use; D001569:Benzodiazepines; D005294:Ferrochelatase; D006220:Haloperidol / Q000627:therapeutic use; D006418:Heme / Q000096:biosynthesis / Q000627:therapeutic use; D006801:Humans; D011163:Hydroxymethylbilane Synthase; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010951:Plasma Exchange; D017118:Porphyria, Acute Intermittent / Q000175:diagnosis / Q000209:etiology / Q000523:psychology / Q000628:therapy; D011379:Prognosis
D000701:Analgesics, Opioid; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D006418:Heme; D001120:Arginine; D000624:5-Aminolevulinate Synthetase; D011163:Hydroxymethylbilane Synthase; D005294:Ferrochelatase; D006220:Haloperidol; D000077152:Olanzapine; C048849:heme arginate